1[1]Brinsden PR, Wdad I, Han SL, et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol, 1995, 102:767-772.
2[2]Agrawal R, Conway C, Sladkevicius P, et al. Serum vascular endothelial growth-factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril, 1998, 70:651-658.
3[3]Akande AV, Mathur RS, Keay SD, et al. The choice of lutesl support following pituitary down regulation, controlled ovarian hyperstimulation and in vitro fertilisation. Br J Obstet Gynaecol, 1996, 103:963-966.
4[4]Pellicer A, Albert C, Mercader A, et al. The pathogenesis of ovarian hyper-stimulation syndrome: in vivo studies in vestigating the role of interleukin-1 beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril, 1999, 71:482-489.
5[5]Navot D, Relou A, Brikenfeld A, et al. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol, 1988, 159:210-216.
6[6]Segal S, Caspeer RF. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in vitro fertilization. Fertil Steril, 1992, 57:1254-1258.
7[7]Smitz J, Camus M, Devroey P, et al. Incidence of severe hyperstimulation syndrome after GnRH agonist /HMG super-ovulation for in vitro fertilization. Hum Reprod, 1990, 5:933-937.
8[8]Blankenstein J, Shalev J, Saadon T, et al. Ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing ovarian follicles. Fertil Steril, 1987, 47:597-606.
